Roxadustat To Overtake Epogen In Treating Anemia In CKD By 2021

The market for the treatment of anemia in chronic kidney disease will see Epogen eroded by biosimilars before the overall segment finally returns to growth following the launch of HIF-PHI inhibitor roxadustat, according to Datamonitor Healthcare's latest forecast.